Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3results about How to "Obvious side effects" patented technology

Preparation method of traditional Chinese medicine combination for treating nephroptosis, pyelonephritis ascites and nephritis

PendingCN122321071Aeasy to useHigh cure rateNephroptosisRegimen
This invention provides a traditional Chinese medicine composition for treating renal edema, pyelonephritis with ascites, and nephritis. It consists of over 20 herbs including Atractylodes lancea, Areca catechu, Saposhnikovia divaricata, and Alisma plantago-aquatica (specific formulation details can be found in the original text). It can be prepared as pills, granules, or decoctions for oral administration. Core efficacy: 1. Promotes diuresis and reduces swelling, eliminating renal ascites; 2. Clears heat and detoxifies, anti-inflammatory and antibacterial (synergistic effect on fungal infections and cervical erosion); 3. Regulates renal function and improves abnormal uric acid metabolism. Treatment plan: Mild cases: Use five basic formulas (①-⑤) composed of Codonopsis pilosula, Poria cocos, etc., taken three times daily; Severe cases: Use a potent diuretic formula containing Akebia trifoliata and Euphorbia pekinensis (one spoonful of pills twice daily); Treatment course is approximately one month, with a follow-up examination after three months. Advantages: Cure rate reaches 90%, low recurrence rate – pure traditional Chinese medicine preparation, no significant toxic side effects; also treats complications (fungal infection, cervical lesions). This treatment plan has been clinically verified through three generations and has significant efficacy in treating renal edema, ascites, and nephritis.
Owner:李爱松

Use of cycloheptapeptides for the preparation of a medicament for reducing body weight

PendingCN122182739AReduce pharmacological activityImprove convenienceMetabolism disorderDigestive system
The present application relates to the use of a cyclic heptapeptide in the preparation of a medicament for reducing body weight. Specifically, the present application discloses a new use of a cyclic heptapeptide Cyclo-[TYVPKAF] or a pharmaceutically acceptable salt thereof in the preparation of a medicament for reducing body weight, preventing or treating a body weight related disease. The body weight related disease includes obesity, overweight, metabolic syndrome, type 2 diabetes, fatty liver, cardiovascular disease or osteoarthritis, etc. The present application first discovers that the specific cyclic heptapeptide has clear and convenient body weight control activity, and in particular, its orally effective characteristics provide a new choice for long-term body weight management.
Owner:SHANGHAI SIXTH PEOPLES HOSPITAL